What We're Reading: Page 190
Industry reads hand-picked by our editors
Nov 03, 2020
-
Reuters
FDA bars critic from review panel of Biogen's controversial Alzheimer's drug
-
STAT
Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles
-
POLITICO
Health agencies resist Trump civil service executive order
-
FiercePharma
Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case
Nov 02, 2020
Oct 30, 2020
-
Associated Press
Lab tests show risks of using CRISPR gene editing on embryos
-
Axios
States beg for Warp Speed billions to distribute COVID-19 vaccines
-
AstraZeneca
AstraZeneca sells commercial rights to two drugs in $400 million deal
-
Bloomberg
How Hims Built An Online Prescription Drug Empire On Outdated Oversight
Oct 29, 2020
-
Science
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
-
Reuters
U.S. drugmakers, bracing for price cuts, shift election support toward Democrats
-
FierceBiotech
Gilead stops 3 filgotinib trials pending FDA feedback on faltering JAK1 inhibitor
-
Bloomberg
Moderna Received $1.1 Billion in Deposits for Covid Vaccines in Quarter
Oct 28, 2020
-
The New York Times
In a Battered New York Office Market, Life Science Is Flourishing
-
STAT
Can boosting the 'bliss molecule' help treat mental health conditions? An oft-failed idea gets another shot
-
USA Today
FDA COVID vaccine chief: We'll be independent, transparent, trustworthy
-
Financial Times
GSK reassures on profits as standard vaccination levels recover
Oct 27, 2020
-
POLITICO
Medicare and Medicaid to cover early Covid vaccine
-
The Boston Globe
Scorpion, seeking to develop 'precision medicine' drugs for cancer, debuts with $108m in funding
-
Kaiser Health News
Florida Fails to Attract Bidders for Canada Drug Importation Program
-
STAT
Covid-19 expert Akiko Iwasaki fights a different virus: sexism in science
Oct 26, 2020
-
FiercePharma
The 20 most influential people in the fight against COVID-19
-
Financial Times
Oxford Covid vaccine trials offer hope for elderly
-
Endpoints News
Biogen chair Stelios Papadopoulos takes his investing experience to the SPAC party, raising $100M for a blank check deal
-
Reuters
FDA delays decision on Spectrum Pharma's drug candidate due to travel curbs
Previous
